Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 12 · above the Ichimoku cloud · RSI 66 · MACD above its signal
None of the 29 investors followed here reported a position in CTEC.L in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CTEC.L trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Convatec Group Plc | Buy Back at price 2.87 per share. | 374.9K | $1.08M |
| Sep 30, 2026 | Convatec Group Plc | Buy Back at price 2.82 per share. | 485.4K | $1.37M |
| Sep 29, 2026 | Convatec Group Plc | Buy Back at price 2.88 per share. | 3.3K | $9.62K |
| Sep 29, 2026 | Fil Limited | — | 1.12M | — |
| Sep 28, 2026 | Convatec Group Plc | Buy Back at price 2.84 per share. | 121.7K | $346.20K |
| Sep 28, 2026 | Fil Limited | — | 2.02M | — |
| Sep 27, 2026 | Convatec Group Plc | Buy Back at price 2.80 per share. | 363.1K | $1.02M |
| Sep 24, 2026 | Convatec Group Plc | Buy Back at price 2.78 per share. | 1.69M | $4.70M |
| Sep 23, 2026 | Convatec Group Plc | Buy Back at price 2.82 per share. | 1.74M | $4.89M |
| Sep 22, 2026 | Convatec Group Plc | Buy Back at price 2.85 per share. | 1.22M | $3.48M |
| Sep 21, 2026 | Convatec Group Plc | Buy Back at price 2.88 per share. | 296.3K | $853.70K |
| Sep 21, 2026 | Blackrock, Inc. | — | 6.77M | — |
| Sep 20, 2026 | Convatec Group Plc | Buy Back at price 2.86 per share. | 578.3K | $1.65M |
| Sep 17, 2026 | Convatec Group Plc | Buy Back at price 2.87 per share. | 1.82M | $5.20M |
| Sep 16, 2026 | Convatec Group Plc | Buy Back at price 2.90 per share. | 748.3K | $2.17M |
| Sep 15, 2026 | Convatec Group Plc | Buy Back at price 2.89 per share. | 1.11M | $3.22M |
| Sep 14, 2026 | Convatec Group Plc | Buy Back at price 2.92 per share. | 798.4K | $2.33M |
| Sep 13, 2026 | Convatec Group Plc | Buy Back at price 2.93 per share. | 1.27M | $3.70M |
| Sep 10, 2026 | Convatec Group Plc | Buy Back at price 2.95 per share. | 930K | $2.74M |
| Sep 9, 2026 | Convatec Group Plc | Buy Back at price 2.96 per share. | 1.11M | $3.28M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.4 | 11.5 | -16.0 | -2.1 | -4.1 | 6.3 | 4.2 | 1.6 | -4.7 | 8.1 | −3.5% | ||
| 2025 | 11.7 | 5.0 | -0.8 | 1.0 | 11.5 | -0.5 | -19.1 | 1.4 | -2.2 | 5.5 | -3.5 | 3.2 | +9.9% |
| 2024 | -1.3 | 2.2 | 16.3 | -12.7 | -0.6 | -5.6 | -0.3 | 2.0 | -5.0 | -6.0 | 10.4 | -6.1 | −9.4% |
| 2023 | 0.7 | -4.2 | 1.9 | -3.8 | -7.7 | 1.2 | 1.7 | 11.4 | -6.3 | -6.2 | 10.1 | 8.6 | +5.0% |
| 2022 | -9.1 | 2.7 | 19.6 | -1.7 | 1.9 | 3.9 | 1.7 | -4.6 | -5.5 | 6.0 | 5.6 | 1.0 | +20.4% |
| 2021 | 0.5 | -5.9 | 4.1 | 11.3 | 8.9 | 1.3 | -1.5 | -4.9 | -4.2 | -1.0 | -9.7 | 0.1 | −3.0% |
| 2020 | 4.8 | -1.4 | -9.0 | 13.9 | -4.5 | -3.6 | 4.0 | -5.8 | -6.7 | 1.1 | 14.4 | -3.7 | +0.4% |
| 2019 | 2.8 | -7.1 | 6.7 | -2.1 | 0.7 | 4.5 | 7.1 | 11.7 | 0.5 | 12.5 | -2.9 | 3.7 | +42.8% |
| 2018 | -1.6 | 2.1 | -3.6 | 9.1 | 6.7 | -8.3 | 3.1 | -2.6 | 9.0 | -30.3 | -6.2 | -8.6 | −32.4% |
| 2017 | 5.1 | -4.0 | 18.2 | 10.1 | 4.2 | -0.2 | -2.7 | -7.7 | -4.5 | -28.5 | -1.0 | 5.9 | −12.1% |
| 2016 | -4.8 | -1.7 | −6.4% |
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Buy / hold / sell counts
No recent headlines.